CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Aqua Medical›
News
Aqua Medical

Aqua Medical

Aqua Medical: Innovating GI disease treatment with vapor-based, endoscopic ablation technology.

HQ
Santa Ana, CA, US
Founded
2016
Loading
Overview
Compare
Fundraising
Employees
News
Library

Latest News About Aqua Medical

Aqua Medical Secures Series B Funding to Advance U.S. Pivotal Trial for Novel Through-the-Scope Type 2 Diabetes Procedure

Aqua Medical

Aqua Medical Secures Series B Funding to Advance U.S. Pivotal Trial for Novel Through-the-Scope Type 2 Diabetes Procedure

Aqua Medical announced a Series B led by Relevance Ventures to complete its U.S. RESTORE-1 pilot study and prepare a planned pivotal trial...

Sep 24, 2026

Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes

Aqua Medical Inc.

Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes

Aqua Medical appointed medical device executive Bob Haggerty president and CEO, effective July 31, 2026.

Aug 4, 2026

Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy

Aqua Medical Inc.

Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapy

Aqua Medical treated the first U.S. patient in its FDA-authorized IDE trial of the investigational PIMA procedure at UNC Health.

Jul 28, 2026

Aqua Medical Highlights 100% Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with its Breakthrough Through-the-Scope Procedure at Digestive Disease Week 2026

Aqua Medical Inc.

Aqua Medical Highlights 100% Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with its Breakthrough Through-the-Scope Procedure at Digestive Disease Week 2026

Aqua Medical presented 12-month clinical follow-up data for its PIMA procedure at Digestive Disease Week 2026.

May 5, 2026

Aqua Medical wins FDA IDE to launch trial for ablation procedure that treats diabetes

MassDevice

Aqua Medical wins FDA IDE to launch trial for ablation procedure that treats diabetes

Aqua Medical received an FDA investigational device exemption for a pilot clinical trial of its PIMA procedure for type 2 diabetes.

Nov 4, 2025